Holen Sie sich die Stockscreener-App
2.64
6.71%
-0.19
Handel nachbörslich:
2.64
Schlusskurs vom Vortag:
$2.83
Offen:
$2.79
24-Stunden-Volumen:
1.59M
Relative Volume:
0.29
Marktkapitalisierung:
$91.20M
Einnahmen:
$2.05M
Nettoeinkommen (Verlust:
$-23.15M
KGV:
-0.3981
EPS:
-6.6319
Netto-Cashflow:
$-16.93M
1W Leistung:
-14.01%
1M Leistung:
+22.79%
6M Leistung:
+216.17%
1J Leistung:
-58.29%
1-Tages-Spanne:
$2.50
$2.83
1-Wochen-Bereich:
$2.405
$3.12
52-Wochen-Spanne:
$0.5562
$6.40
iBio Inc Stock (IBIO) Company Profile
Firmenname
iBio Inc
Sektor
Branche
Telefon
302-355-0650
Adresse
600 Madison Avenue, Suite 1601, New York, NY
Compare IBIO vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IBIO
iBio Inc
|
2.64 | 97.76M | 2.05M | -23.15M | -16.93M | -6.6319 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.14 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
iBio Inc Stock (IBIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-21 | Eingeleitet | Oppenheimer | Outperform |
| 2025-10-17 | Eingeleitet | Leerink Partners | Outperform |
| 2024-05-28 | Eingeleitet | Chardan Capital Markets | Buy |
| 2021-11-29 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-01-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-06-26 | Eingeleitet | Alliance Global Partners | Buy |
Alle ansehen
iBio Inc Aktie (IBIO) Neueste Nachrichten
iBio (NASDAQ:IBIO) Upgraded by JonesTrading to Strong-Buy Rating - MarketBeat
Jones Trading Initiates Coverage of iBio (IBIO) with Buy Recommendation - Nasdaq
JonesTrading Initiates IBio Inc(IBIO.US) With Buy Rating, Announces Target Price $7 - 富途牛牛
iBio (IBIO) Receives New 'Buy' Rating from Jones Trading | IBIO Stock News - GuruFocus
iBio (NYSE:IBIO) Now Covered by Analysts at JonesTrading - MarketBeat
Jones Trading initiates iBio stock with buy rating on obesity platform - Investing.com Australia
Jones Trading initiates iBio stock with buy rating on obesity platform By Investing.com - Investing.com South Africa
Ibio SEC Filings - Stock Titan
Revenue per share of iBio, Inc. – MUN:0JV0 - TradingView
IBio enters open market sale agreement with Jefferies - marketscreener.com
IBio Files $200 Million Mixed Shelf Offering - marketscreener.com
iBio Launches Up to $100 Million ATM Program With Jefferies to Bolster Liquidity - TradingView
iBio (NYSE: IBIO) launches $100M at-the-market stock offering with Jefferies - Stock Titan
IBio Inc files for mixed shelf of up to $200 million - marketscreener.com
iBio Inc Files For Mixed Shelf Of Upto $200 Million - TradingView
Ken Johnson - Crain's Chicago Business
IBIO: Pipeline advances in obesity and cardiovascular drugs with strong financial backing and near-term data - TradingView
IBIO: Advancing next-gen obesity therapies with strong financials and key data readouts ahead - TradingView
Growth Report: Will iBio Inc benefit from green energy policiesMarket Movers & Verified Momentum Stock Alerts - baoquankhu1.vn
LifeSci Capital Maintains IBio Inc(IBIO.US) With Buy Rating, Maintains Target Price $5 - 富途牛牛
Aug Selloffs: Is Beazer Homes USA Inc forming a breakout patternTrade Entry Report & Long-Term Growth Portfolio Plans - baoquankhu1.vn
iBio (NYSEMKT:IBIO) Stock Price Up 2.9%Should You Buy? - MarketBeat
How do insiders feel about iBio Inc.Rate Cut & Step-by-Step Swing Trade Plans - mfd.ru
iBio to Participate in Upcoming Investor Conferences - The Manila Times
iBio leaders join fireside chats at Oppenheimer and Leerink healthcare events - Stock Titan
Critical Review: iBio (NYSE:IBIO) versus Vaxxinity (NASDAQ:VAXX) - Defense World
IBio, Inc. (IBIO) Stock: Price Predictions & Analysis - thedetroitbureau.com
ADAR1 discloses 4.4% iBio (IBIO) ownership in updated 13G filing - Stock Titan
Brookline Cap M Weighs in on iBio's Q3 Earnings (NYSE:IBIO) - MarketBeat
IBIO PE Ratio & Valuation, Is IBIO Overvalued - Intellectia AI
iBio (NASDAQ:IBIO) Rating Lowered to Sell at Wall Street Zen - MarketBeat
IBIO Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
IBIO Should I Buy - Intellectia AI
Stock Recap: Will iBio Inc outperform its industry peersJuly 2025 Snapshot & Accurate Buy Signal Notifications - baoquankhu1.vn
IBIO: Chardan Capital Maintains 'Buy' Rating with Steady Price T - GuruFocus
iBio's (IBIO) Buy Rating Reiterated at Chardan Capital - MarketBeat
Can iBio Inc. stock attract ESG capital inflows2025 Fundamental Recap & Low Risk Entry Point Guides - mfd.ru
iBio Reports Q2 Fiscal Year 2026 Financial Results and Provides Corporate Update - The Manila Times
IBIO Inc (NASDAQ:IBIO) Secures $26 Million Lifeline Amid Quarterly Earnings Miss - ChartMill
iBio (IBIO) Bolsters Pipeline with $26M Financing - GuruFocus
iBio Earnings Review: Q2 Summary - Benzinga
iBio, Inc. SEC 10-Q Report - TradingView
iBio, Inc. (IBIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release - MSN
IBIO stock soars 12% pre-market after company announces $26 million private placement - MSN
Fed Watch: Will iBio Inc benefit from green energy policiesMarket Growth Summary & Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
How iBio Inc. stock reacts to inflationary pressuresGold Moves & Free Expert Verified Stock Movement Alerts - mfd.ru
Forecast Cut: What is the implied volatility of Teck Resources LimitedTrade Signal Summary & Technical Confirmation Trade Alerts - baoquankhu1.vn
IBIO Stockholders Sell Shares Without Company Receiving Proceeds - GuruFocus
iBio (NASDAQ:IBIO) Stock Price Down 3.6%Here's Why - MarketBeat
What is the PEG ratio of iBio Inc.2025 EndofYear Setup & Growth Focused Investment Plans - mfd.ru
ImmunityBio Stock Rises 25.3% to $6.92 - intellectia.ai
Finanzdaten der iBio Inc-Aktie (IBIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.69%
0.68%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):